Scientists at MIT have created variants of the peptides from a South American wasp's venom that can kill bacteria but are nontoxic to human cells.
The venom of insects such as wasps and bees is full of compounds that can kill bacteria, according to the study published in the journal Nature Communications Biology.
However, many of these compounds are also toxic for humans, making it impossible to use them as antibiotic drugs.
In a study of mice, the researchers found that their strongest peptide could completely eliminate Pseudomonas aeruginosa, a strain of bacteria that causes respiratory and other infections and is resistant to most antibiotics.
"We've repurposed a toxic molecule into one that is a viable molecule to treat infections," said Cesar de la Fuente-Nunez from the Massachusetts Institute of Technology (MIT) in the US.
"By systematically analysing the structure and function of these peptides, we've been able to tune their properties and activity," said Fuente-Nunez.
The peptide that researchers focused on was isolated from a wasp known as Polybia paulista.
This peptide is small enough -- only 12 amino acids -- that the researchers believed it would be feasible to create some variants of the peptide and test them to see if they might become more potent against microbes and less harmful to humans.
Like many other antimicrobial peptides, this venom-derived peptide is believed to kill microbes by disrupting bacterial cell membranes.
To measure the peptides' toxicity, the researchers exposed them to human embryonic kidney cells grown in a lab dish.
They selected the most promising compounds to test in mice infected with Pseudomonas aeruginosa, a common source of respiratory and urinary tract infections, and found that several of the peptides could reduce the infection.
One of them, given at a high dose, could eliminate it completely, researchers said.
"After four days, that compound can completely clear the infection, and that was quite surprising and exciting because we don't typically see that with other experimental antimicrobials or other antibiotics that we've tested in the past with this particular mouse model," Fuente-Nunez said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
